H.C. Wainwright analyst Boobalan Pachaiyappan reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) today and set a price target of $10.00. The company’s shares closed last Friday at $3.70.
According to TipRanks, Pachaiyappan is an analyst with an average return of -3.6% and a 44.00% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Brainsway, Gain Therapeutics, and Aeterna Zentaris.
Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.00, implying a 170.27% upside from current levels. In a report released on September 12, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $6.19 and a one-year low of $2.80. Currently, Gain Therapeutics has an average volume of 33.16K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
Read More on GANX:
- Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
- Gain Therapeutics initiated with a Buy at Maxim
- Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
- Gain Therapeutics announces preclinical data from drug candidate GT-02287
- Gain Therapeutics expects cash to fund operations into Q3 of 2024
